Trial
NCT01391130
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Metastatic Clear Cell Renal Cell Carcinoma
Intervention
LY2510924
Why stopped
Study Terminated due to Insufficient Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-23